Clinical Implications of Updated Data from EHA 2024

Opinion
Video

Key opinion leaders evaluate the clinical implications of updated data presented at EHA 2024, interpreting how these findings may influence future treatment strategies in multiple myeloma.

Video content above is prompted by the following:

  • What Is your current strategy and treatment option for maintenance therapy in NDMM for transplant eligible??
  • Please share your thoughts on the updated data from CASSOPEIA. (Moreau P et al. EHA 2024, Abstract S204)
  • How does the data impact frontline treatment for transplant eligible NDMM?

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content